CA3242449A1 - Use of aminopyrazole compounds - Google Patents
Use of aminopyrazole compoundsInfo
- Publication number
- CA3242449A1 CA3242449A1 CA3242449A CA3242449A CA3242449A1 CA 3242449 A1 CA3242449 A1 CA 3242449A1 CA 3242449 A CA3242449 A CA 3242449A CA 3242449 A CA3242449 A CA 3242449A CA 3242449 A1 CA3242449 A1 CA 3242449A1
- Authority
- CA
- Canada
- Prior art keywords
- aminopyrazole compounds
- jak
- compounds
- aminopyrazole
- atopic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21217736 | 2021-12-24 | ||
| EP21217736.4 | 2021-12-24 | ||
| PCT/EP2022/087698 WO2023118555A1 (en) | 2021-12-24 | 2022-12-23 | Use of aminopyrazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242449A1 true CA3242449A1 (en) | 2023-06-29 |
Family
ID=79025165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242449A Pending CA3242449A1 (en) | 2021-12-24 | 2022-12-23 | Use of aminopyrazole compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049775A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4452970A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024545293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240124925A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118541364A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022418280A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242449A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007863A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023118555A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021335500A1 (en) | 2020-09-04 | 2023-05-04 | Elanco Us Inc. | Palatable formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3951899A (en) | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| RS53382B (sr) | 2008-08-20 | 2014-10-31 | Zoetis Llc | Jedinjenja pirol [2,3-d]pirimidina |
| AU2012312303B2 (en) | 2011-09-22 | 2016-09-15 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
| WO2014146246A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
| AU2017376398B2 (en) | 2016-12-14 | 2021-07-15 | Intervet International B.V. | Aminopyrazoles as selective janus kinase inhibitors |
| KR20220119024A (ko) * | 2019-12-20 | 2022-08-26 | 인터벳 인터내셔널 비.브이. | 피라졸 제약 조성물 |
-
2022
- 2022-12-23 WO PCT/EP2022/087698 patent/WO2023118555A1/en not_active Ceased
- 2022-12-23 US US18/721,916 patent/US20250049775A1/en active Pending
- 2022-12-23 JP JP2024537401A patent/JP2024545293A/ja active Pending
- 2022-12-23 CA CA3242449A patent/CA3242449A1/en active Pending
- 2022-12-23 AU AU2022418280A patent/AU2022418280A1/en active Pending
- 2022-12-23 CN CN202280084861.5A patent/CN118541364A/zh active Pending
- 2022-12-23 KR KR1020247020622A patent/KR20240124925A/ko active Pending
- 2022-12-23 MX MX2024007863A patent/MX2024007863A/es unknown
- 2022-12-23 EP EP22844123.4A patent/EP4452970A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240124925A (ko) | 2024-08-19 |
| JP2024545293A (ja) | 2024-12-05 |
| US20250049775A1 (en) | 2025-02-13 |
| CN118541364A (zh) | 2024-08-23 |
| AU2022418280A1 (en) | 2024-06-13 |
| MX2024007863A (es) | 2024-08-30 |
| WO2023118555A1 (en) | 2023-06-29 |
| EP4452970A1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| PH12019501846A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| PH12018502472A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| MX389697B (es) | Nuevos derivados de pirazolopirimidina. | |
| WO2020132661A3 (en) | Inhibitors of fibroblast activation protein | |
| EP4566675A3 (en) | Heterocyclic compounds as immunomodulators | |
| EP4520328A3 (en) | Heterocyclic compounds as immunomodulators | |
| MX390535B (es) | Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer. | |
| MX2022004989A (es) | Composiciones farmaceuticas de albumina y rapamicina. | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| WO2008045393A3 (en) | Imidazo- and triazolo-pyridine compounds and methods of use therof | |
| PL375204A1 (en) | Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| MXPA05009304A (es) | Derivados de indol utiles para el tratamiento de enfermedades. | |
| WO2012047587A3 (en) | Mdm2 inhibitors for treatment of ocular conditions | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| EP4338802A3 (en) | Tyk2 inhibitors, uses, and methods for production thereof | |
| PH12019502365A1 (en) | New bicyclic pyrazole derivatives | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| WO2006058868A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| MX2020001404A (es) | Dihidrooxadiazinonas. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240705 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20240828 |